Novartis To Buy Merck Spin-Off Calypso Biotech For Up To $375M
By Yeji Jesse Lee · January 8, 2024, 6:01 PM EST
Swiss pharmaceutical giant Novartis is buying European company Calypso Biotech in a deal that could be worth up to $375 million, according to an announcement from Calypso on Monday, marking one...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login